Cochlear Ltd COH

Morningstar Rating
A$281.41 −2.80 (0.99%)
View Full Chart

Company Report

Elevated Growth Unlikely to Stay; Cochlear Shares Remain Expensive

Cochlear is the market leader in cochlear implants with consistent share of roughly 60% across developed markets. Cochlear implants became the standard of care many years ago for children in developed markets with profound hearing loss or deafness. With this market segment largely penetrated, the company is looking elsewhere for growth with developed-markets adults the next primary focus and emerging-markets children after that.

Price vs Fair Value

COH is trading at a 88% premium.
Price
A$281.41
Fair Value
A$285.00
Uncertainty
Medium
1-Star Price
A$667.91
5-Star Price
A$117.70
Economic Moat
Glx
Capital Allocation
Byvgvxnl

Bulls Say, Bears Say

Bulls

There are signs Cochlear is looking to expand beyond the hearing market with the investment in Nyxoah, a company focused on development of a hypoglossal nerve stimulation therapy for the treatment of obstructive sleep apnea.

Bears

Growth in the cochlear implant market is becoming more costly to achieve, limiting the potential upside to earnings.

News

Trading Information

Previous Close Price
A$284.21
Day Range
A$281.01284.99
52-Week Range
A$237.69350.31
Bid/Ask
A$281.04 / A$285.00
Market Cap
A$18.43 Bil
Volume/Avg
176,341 / 162,972

Key Statistics

Price/Earnings (Normalized)
46.26
Price/Sales
8.27
Dividend Yield (Trailing)
1.46%
Dividend Yield (Forward)
1.49%
Total Yield
1.69%

Company Profile

Cochlear is the leading cochlear implant device manufacturer with around 60% global market share. Developed markets contribute 80% of group revenue where cochlear implants are the standard of care for children with severe to profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2020, 49% of revenue came from the Americas, 35% from Europe, the Middle East, and Africa, and 16% from the Asia-Pacific segment.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Large Growth
Total Number of Employees
4,500

Competitors

Valuation

Metric
COH
RMD
DEMANT
Price/Earnings (Normalized)
46.2629.8222.47
Price/Book Value
10.017.106.23
Price/Sales
8.277.262.63
Price/Cash Flow
47.5625.0714.52
Price/Earnings
COH
RMD
DEMANT

Financial Strength

Metric
COH
RMD
DEMANT
Quick Ratio
1.591.180.75
Current Ratio
2.302.591.42
Interest Coverage
51.6328.676.32
Quick Ratio
COH
RMD
DEMANT

Profitability

Metric
COH
RMD
DEMANT
Return on Assets (Normalized)
14.79%16.71%8.21%
Return on Equity (Normalized)
21.59%25.48%27.51%
Return on Invested Capital (Normalized)
18.89%20.37%12.10%
Return on Assets
COH
RMD
DEMANT

Medical Devices Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Abbott Laboratories
ABT
JvtztbqtMdbsd$195.6 Bil
Stryker Corp
SYK
NlbjfsfnlPwlh$137.3 Bil
Boston Scientific Corp
BSX
YlvcxmwSksszxr$122.7 Bil
Medtronic PLC
MDT
NzcllttlGxnyk$114.6 Bil
Edwards Lifesciences Corp
EW
DghhgkdvkHnrdcw$40.1 Bil
Koninklijke Philips NV ADR
PHG
XvhPcw$30.7 Bil
DexCom Inc
DXCM
BfgzxjfbkWwvjq$27.0 Bil
Steris PLC
STE
YmdjcwnlnXfkqp$23.6 Bil
Zimmer Biomet Holdings Inc
ZBH
WwpsfzdgCch$22.0 Bil
Insulet Corp
PODD
CbvqhsksbNjcwtd$16.3 Bil

Sponsor Center